Recursion Pharmaceuticals, Inc. RXRX Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s current debt?
- Recursion Pharmaceuticals, Inc. (RXRX) reported current debt of $9.27M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s current debt changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s current debt increased by 7.9% year-over-year, from $8.59M to $9.27M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s current debt?
- Over 2 years (2023 to 2025), Recursion Pharmaceuticals, Inc.'s current debt has grown at a 1389.1% compound annual growth rate (CAGR), from $41K to $9.09M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.